All posts by admin

18Mar/14

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the … – Lexology (registration)

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the
Lexology (registration)
The European Medicines Agency (“EMEA”) made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in September 2013, it approved Europe’s first biosimilar antibody. The drug is Inflectra which is a

18Mar/14

Asia-Pacific non-small cell lung cancer therapeutics market to reach $2.9 … – Times of India


The Pharma Letter

Asia-Pacific non-small cell lung cancer therapeutics market to reach $2.9
Times of India
MUMBAI: The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion
MarketReserachReports.com: Non-Small Cell Lung Cancer Therapeutics Market MENAFN.COM

all 5 news articles »